Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “Moxetumomab pasudotox is an investigational, first-in-class immunotoxin which we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results